Numerous clinical studies have demonstrated that antiangiogenic therapy, blocking VEGFR, used in human cancers is associated with a reduction of tumour-infiltrating FOXP3+ Treg cells (145–147). The gene discussed is FOXP3; the disease is neoplasm.